GREENWOOD VILLAGE, Colo., Dec. 16, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities, issued a statement in response to recent publications about the Company by anonymous short sellers. The Company believes increased volatility and volume in its common stock is a result of factually inaccurate and materially misleading information being published on the internet about the Company. These anonymous publications disclose that the authors stand to benefit financially from a decline in Ampio's stock.
The Company is investigating the claims that were made and is evaluating potential legal recourse to protect the shareholders and officers of the Company.
Don Wingerter, Chief Executive Officer, stated "Ampio's Board of Directors stands behind the integrity of its science, management, products, clinical trials and public filings. The Company's material progress in attaining regulatory approval for Zertane™, Ampion™ and Optina™ reinforces our confidence in Ampio's fundamentals, product strategy, and positive outlook moving forward."
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
Contact: -- Investor Relations --
Ampio Pharmaceuticals, Inc.-- 720-437-6500
|SOURCE Ampio Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved